NASDAQ:SSKN - STRATA Skin Sciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.84 -0.03 (-1.60 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$1.84
Today's Range$1.82 - $1.89
52-Week Range$1.06 - $2.81
Volume69,033 shs
Average Volume139,753 shs
Market Capitalization$13.20 million
P/E Ratio0.93
Dividend YieldN/A
STRATA Skin Sciences logoSTRATA Skin Sciences, Inc., a medical technology company, engages in developing and commercializing products for the treatment of dermatological disorders. Its products include XTRAC and VTRAC devices used for the treatment of psoriasis, vitiligo, and other skin disorders; and MelaFind system, an instrument for aiding dermatologists in the evaluation of clinically atypical pigmented skin lesions, when a dermatologist chooses to obtain additional information before making a final decision to biopsy in order to rule out melanoma. The company was formerly known as MELA Sciences, Inc. and changed its name to STRATA Skin Sciences, Inc. in December 2015. STRATA Skin Sciences, Inc. was founded in 1989 and is based in Horsham, Pennsylvania.

Receive SSKN News and Ratings via Email

Sign-up to receive the latest news and ratings for SSKN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments


Debt-to-Equity Ratio0.35
Current Ratio1.15
Quick Ratio0.81


Trailing P/E Ratio0.93
Forward P/E Ratio-8.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$31.45 million
Price / Sales0.41
Cash Flow$0.4779 per share
Price / Cash3.85
Book Value$5.46 per share
Price / Book0.34


EPS (Most Recent Fiscal Year)$1.97
Net Income$-18,830,000.00
Net Margins-60.23%
Return on Equity-36.19%
Return on Assets-17.75%


Outstanding Shares7,060,000
Market Cap$13.20

STRATA Skin Sciences (NASDAQ:SSKN) Frequently Asked Questions

What is STRATA Skin Sciences' stock symbol?

STRATA Skin Sciences trades on the NASDAQ under the ticker symbol "SSKN."

When did STRATA Skin Sciences' stock split? How did STRATA Skin Sciences' stock split work?

Shares of STRATA Skin Sciences reverse split before market open on Thursday, July 10th 2014. The 1-10 reverse split was announced on Thursday, July 3rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 9th 2014. An investor that had 100 shares of STRATA Skin Sciences stock prior to the reverse split would have 10 shares after the split.

How were STRATA Skin Sciences' earnings last quarter?

STRATA Skin Sciences Inc (NASDAQ:SSKN) announced its quarterly earnings results on Thursday, May, 12th. The medical device company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by $0.08. The medical device company had revenue of $7.62 million for the quarter, compared to the consensus estimate of $9.15 million. STRATA Skin Sciences had a negative net margin of 60.23% and a negative return on equity of 36.19%. View STRATA Skin Sciences' Earnings History.

What price target have analysts set for SSKN?

1 Wall Street analysts have issued 1-year price objectives for STRATA Skin Sciences' stock. Their predictions range from $3.00 to $3.00. On average, they expect STRATA Skin Sciences' stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 63.0% from the stock's current price. View Analyst Ratings for STRATA Skin Sciences.

What is the consensus analysts' recommendation for STRATA Skin Sciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STRATA Skin Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about STRATA Skin Sciences stock?

Here are some recent quotes from research analysts about STRATA Skin Sciences stock:
  • 1. According to Zacks Investment Research, "Strata Skin Sciences, Inc. is a medical technology company which focused on the dermatology market. Its products include the XTRAC laser(R) and VTRAC(R) excimer lamp systems for treatment of psoriasis, vitiligo and other skin conditions as well as the MelaFind (R) system used for identification and management of melanoma skin cancer. Strata Skin Sciences, Inc., formerly known as MELA Sciences, Inc., is based in Horsham, Pennsylvania. " (6/5/2018)
  • 2. HC Wainwright analysts commented, "We note that PE is typically characterized by damage to he epithelium of the cornea in a pinpoint pattern. Potential causes of PE may include dry eye disease, blepharitis and bacterial conjunctivitis. The number of patients with corneal epitheliopathies in the U.S. could be over 76M, and current therapies have limited efficacy. Investors may recall that OBG is being developed for the acceleration of re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK). EyeGate expects to address the outstanding item cited by the FDA in the IDE for PRK in the current quarter. If so, a clinical trial in PE may start in 2H 2018, according to the management. In our view, the addition of PE could significantly expand the addressable market of OBG. In the wake of this update, we reiterate our Buy rating and $3 price target." (5/31/2018)

Who are some of STRATA Skin Sciences' key competitors?

Who are STRATA Skin Sciences' key executives?

STRATA Skin Sciences' management team includes the folowing people:
  • Mr. Frank J. McCaney, Interim CFO & Director (Age 63)
  • Mr. Michael R. Stewart, Independent Consultant (Age 61)
  • Dr. Dolev Rafaeli, Interim CEO (Age 54)
  • Mr. Jay Sturm, Corp. Counsel & Corp. Sec. (Age 62)
  • Dr. Darrell S. Rigel M.D., Ms, Faad, Chief Medical Advisor (Age 67)

Has STRATA Skin Sciences been receiving favorable news coverage?

News stories about SSKN stock have trended somewhat positive recently, Accern reports. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. STRATA Skin Sciences earned a media sentiment score of 0.04 on Accern's scale. They also gave media headlines about the medical device company an impact score of 47.00 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of STRATA Skin Sciences?

Shares of SSKN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is STRATA Skin Sciences' stock price today?

One share of SSKN stock can currently be purchased for approximately $1.84.

How big of a company is STRATA Skin Sciences?

STRATA Skin Sciences has a market capitalization of $13.20 million and generates $31.45 million in revenue each year. The medical device company earns $-18,830,000.00 in net income (profit) each year or $1.97 on an earnings per share basis. STRATA Skin Sciences employs 98 workers across the globe.

How can I contact STRATA Skin Sciences?

STRATA Skin Sciences' mailing address is 100 LAKESIDE DRIVE SUITE 100, HORSHAM PA, 19044. The medical device company can be reached via phone at 215-619-3200 or via email at [email protected]

MarketBeat Community Rating for STRATA Skin Sciences (NASDAQ SSKN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  126 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  236
MarketBeat's community ratings are surveys of what our community members think about STRATA Skin Sciences and other stocks. Vote "Outperform" if you believe SSKN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SSKN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by Staff

Featured Article: How Short Selling Works

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.